Sugi Predict

Sugi Predict / Compounds / SCHEMBL365301

SCHEMBL365301

SCHEMBL365301

CCOc1ncccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 4/20 0.36
▸ HPGD P15428 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ LIPE Q05469 2/20 0.35
▸ PDE1A P54750 1/20 0.35
▸ PDE1B Q01064 1/20 0.35
▸ PDE1C Q14123 1/20 0.35
▸ LPL P06858 2/20 0.35
▸ LIPG Q9Y5X9 2/20 0.35
▸ TSHR P16473 2/20 0.35
▸ SLC6A2 P23975 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ UCHL1 P09936 1/20 0.34
▸ LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29900384 1.00 L3MBTL1 (0.36) L3MBTL1HPGDSMN1; SMN2LIPEPDE1A
SCHEMBL9998673 0.88 LPL (0.36) HPGDSMN1; SMN2LIPEPDE1APDE1B
SCHEMBL30138169 0.88 LPL (0.36) HPGDSMN1; SMN2LIPEPDE1APDE1B
SCHEMBL30292561 0.84 APLNR (0.38) LIPELPLLIPGNPC1UCHL1
SCHEMBL1484864 0.84 APLNR (0.38) LIPELPLLIPGNPC1UCHL1
Water SCHEMBL2513501 0.83 APLNR (0.37) LIPELPLLIPGNPC1UCHL1
SCHEMBL25300352 0.82 LIPE (0.42) LIPE
SCHEMBL29879749 0.82 LIPE (0.42) LIPE
SCHEMBL20428054 0.82 LIPE (0.35) LIPELPLLIPG
SCHEMBL1360465 0.82 DGAT1 (0.47) L3MBTL1HPGDLIPELPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117447475-A Pyrazolo [4,3-b ] pyridines and imidazo [1,5-a ] pyrimidines as PDE1 inhibitors H.隆德贝克有限公司 2024-01-26 — — CN disclosed
US-11851425-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines H. LUNDBECK A/S (DK) 2023-12-26 — — US disclosed
US-11834449-B2 TYK2 inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-05 — — US disclosed
US-11834449-B2 TYK2 inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-05 — — US disclosed
CN-111511742-B Pyrazolo [4,3-b ] pyridines and imidazo [1,5-a ] pyrimidines as PDE1 inhibitors H.隆德贝克有限公司 2023-10-27 — — CN disclosed
CN-111556871-B 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors H.隆德贝克有限公司 2023-07-07 — — CN disclosed
CN-111491936-B Macrocyclic compounds as PDE1 inhibitors H.隆德贝克有限公司 2023-07-04 — — CN disclosed
US-11634416-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines H. LUNDBECK A/S (DK) 2023-04-25 — — US disclosed
US-11535611-B2 Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors H. LUNDBECK A/S (DK) 2022-12-27 — — US disclosed
US-11535611-B2 Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors H. LUNDBECK A/S (DK) 2022-12-27 — — US disclosed
WO-2018007249-A1 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS H. LUNDBECK A/S (DK) 2018-01-11 — — WO disclosed
US-20180000786-A1 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors H. LUNDBECK A/S (DK) 2018-01-04 — — US disclosed
US-20180000786-A1 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors H. LUNDBECK A/S (DK) 2018-01-04 — — US disclosed
EP-2593433-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-26 — — EP disclosed
US-8772343-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 — — US disclosed
WO-2013093688-A1 SULFONAMIDE DERIVATIVES AND USE THEREOF AS VGSC INHIBITORS PFIZER LIMITED (GB) 2013-06-27 — — WO disclosed
WO-2013093688-A1 SULFONAMIDE DERIVATIVES AND USE THEREOF AS VGSC INHIBITORS PFIZER LIMITED (GB) 2013-06-27 — — WO disclosed
EP-2593433-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 — — EP disclosed
US-20130116285-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-09 — — US disclosed
WO-2012007877-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834449-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 L3MBTL1 914/4885HPGD 4476/4885SMN1; SMN2 1145/4885
US-11851425-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines PDE3B, PDE1B, PDE12 L3MBTL1 4425/4885HPGD 272/4885SMN1; SMN2 108/4885
US-11634416-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines PDE1B, PDE3B, PDE1A L3MBTL1 4584/4885HPGD 414/4885SMN1; SMN2 2582/4885
US-20180000786-A1 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors PDE3A, PDE5A, PDE12 L3MBTL1 4312/4885HPGD 330/4885SMN1; SMN2 422/4885
US-11535611-B2 Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors PDE5A, PDE12, PDE3A L3MBTL1 4500/4885HPGD 264/4885SMN1; SMN2 749/4885
US-20130116285-A1 Chemical Compounds SCN1A, SCN10A, SCN1B L3MBTL1 3977/4885HPGD 3439/4885SMN1; SMN2 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.